[Effect of arotinolol on insulin secretion and insulin clearance rate in patients with Graves' disease].
Glucose-induced insulin secretion, 24-h urinary C-peptide (CPR) and euglycemic clamp were examined in five patients with hyperthyroid Graves' disease before and 2 weeks after treatment with arotinolol (20 mg/day, p.o.). Plasma glucose and insulin responses to oral administration of 75 g glucose were not changed by arotinolol treatment. 24-h urinary CPR and basal posthepatic insulin delivery rate (BPIDR) as an indicator of insulin secretion were significantly suppressed by arotinolol. Glucose infusion rate (GIR) as an indicator of insulin sensitivity and glucose clearance rate (GCR) were not influenced by arotinolol therapy. Insulin clearance rate (ICR) was significantly suppressed by arotinolol. These findings suggest that arotinolol inhibits insulin secretion by decreasing ICR but does not attenuate insulin release induced by glucose in hyperthyroid patients, and that insulin sensitivity and GCR are not affected by arotinolol.
Ohguni
S
S
Department of Medicine, Shimane Medical University, Izumo, Japan.
Notsu
K
K
Tanaka
J
J
Sato
T
T
Kato
Y
Y
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D003864:Depression, Chemical; D005260:Female; D005947:Glucose / Q000378:metabolism; D006111:Graves Disease / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D007328:Insulin; D011412:Propanolamines; C024523:arotinolol; D005947:Glucose